Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies

@article{Ratti2013FullCN,
  title={Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies},
  author={E. Ratti and P. Bettica and Robert Alexander and G. Archer and D. Carpenter and G. Evoniuk and R. Gomeni and Erica L. Lawson and M. L{\'o}pez and H. Millns and E. Rabiner and D. Trist and Michael Trower and S. Zamuner and R. Krishnan and M. Fava},
  journal={Journal of Psychopharmacology},
  year={2013},
  volume={27},
  pages={424 - 434}
}
  • E. Ratti, P. Bettica, +13 authors M. Fava
  • Published 2013
  • Psychology, Medicine
  • Journal of Psychopharmacology
    • Full, persistent blockade of central neurokinin-1 (NK1) receptors may be a potential antidepressant mechanism. The selective NK1 antagonist orvepitant (GW823296) was used to test this hypothesis. A preliminary positron emission tomography study in eight male volunteers drove dose selection for two randomized six week studies in patients with major depressive disorder (MDD). Displacement of central [11C]GR205171 binding indicated that oral orvepitant doses of 30–60 mg/day provided >99% receptor… CONTINUE READING
    View on SAGE
    ncbi.nlm.nih.gov
    42 Citations
    Background Citations
    14

    Supplemental Clinical Trials

    Interventional Clinical Trial
    A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
    This is a 6-week, randomised, multicenter, double-blind, placebo controlled, fixed dose parallel group study to assess the efficacy and safety of orvepitant (30 and 60 mg/day… Expand
    ConditionsDepressive Disorder
    InterventionDrug, Other
    GlaxoSmithKline
    March 2009 - June 2010
    Interventional Clinical Trial
    A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
    This is a 6-week, randomised, multicenter, double-blind, placebo controlled, fixed dose parallel group study to assess the efficacy and safety of orvepitant (30 and 60 mg/day… Expand
    ConditionsDepressive Disorder, Major
    InterventionDrug, Other
    GlaxoSmithKline
    March 2009 - June 2010

    Paper Mentions

    Blog Post
    Can a Failed Schizophrenia Drug Prevent PTSD?
    The Neurocritic
    10 July 2014
    Interventional Clinical Trial
    Orvepitant (GW823296) in Adult Post Traumatic Stress Disorder
    This is a 12-week, randomized, multicenter, double-blind, placebo controlled, fixed-dose parallel group study to assess the efficacy and safety of orvepitant (60 mg/day) versus… Expand
    ConditionsPost-Traumatic Stress Disorder
    InterventionDrug, Other
    GlaxoSmithKline
    November 2009 - June 2010
    42 Citations
    Citation Type

    Citation Type

    Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder.
    • 1
    • PDF
    Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial
    • 3
    Why receptor reserve matters for neurokinin1 (NK1) receptor antagonists
    • 13
    Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial
    • 3
    • PDF
    NK1 receptor antagonists for depression: Why a validated concept was abandoned.
    • 17
    Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia.
    • 14
    • PDF
    Substance P and the Neurokinin-1 Receptor: The New CRF.
    • 22
    A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients
    • 15
    • PDF
    Neurokinin-1 Receptor Antagonists: Promising Agents in the Treatment of Chronic Pruritus
    Neurokinin‐1 receptor antagonist orvepitant is an effective inhibitor of itch‐associated response in a Mongolian gerbil model of scratching behaviour
    • 6

    References

    SHOWING 1-10 OF 43 REFERENCES
    Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression
    • 236
    • Highly Influential
    • PDF
    Lack of Efficacy of the Substance P (Neurokinin1 Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder
    • 265
    Results From 2 Randomized, Double-Blind, Placebo-Controlled Studies of the Novel NK1 Receptor Antagonist Casopitant in Patients With Major Depressive Disorder
    • 58
    Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    • 126
    • Highly Influential
    A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder.
    • 103
    • Highly Influential
    Imaging substance P receptors (NK1) in the living human brain using positron emission tomography.
    • 151
    Do substance P and the NK1 receptor have a role in depression and anxiety?
    • S. McLean
    • Medicine
    • Current pharmaceutical design
    • 2005
    • 75
    Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function.
    • 284
    • PDF
    Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: Comparison with antidepressant drugs
    • 70
    Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    • 170
    • Highly Influential